विवरण

Over the past decade, invasive techniques for diagnosing and monitoring cancers are slowly being replaced by non-invasive methods such as liquid biopsy. Liquid biopsies have drastically revolutionized the field of clinical oncology, offering ease in tumor sampling, continuous monitoring by repeated sampling, devising personalized therapeutic regimens, and screening for therapeutic resistance. A study by StrategyHelix indicates that the global liquid biopsy market is expected to increase by US$ 6,579.5 मिलियन से 2022 को 2028, का सीएजीआर जुटाना 16.1% पूर्वानुमान अवधि के दौरान.

रिपोर्ट अवधि के लिए नवीनतम बाज़ार आकार डेटा प्रदान करती है 2018-2021 और पूर्वानुमान करें 2028 covering key market aspects like sales value for liquid biopsy. The global liquid biopsy market is segmented on the basis of therapy, application, biomarker type, technology, and region. Based on therapy, the global liquid biopsy market is categorized into oncology, noninvasive prenatal testing (NIPT), others (e.g. organ transplant). The NIPT segment captured the largest share of the market in 2021. On the basis of application, the global liquid biopsy market has been segmented into diagnosis, early detection/screening, monitoring, therapy guidance. The early detection/screening segment held the largest share of the global liquid biopsy market in 2021 and is anticipated to hold its share during the forecast period. By biomarker type, the global liquid biopsy market has been segmented into cell-free nucleic acids, circulating tumor cells, others. In 2021, the cell-free nucleic acids segment made up the largest share of revenue generated by the liquid biopsy market. Based upon technology, the global liquid biopsy market is categorized into next-generation sequencing (NGS), polymerase chain reaction (PCR), others. Among these, the next-generation sequencing (NGS) segment was accounted for the highest revenue generator in 2021. In terms of geography, the global liquid biopsy market has been segmented into Asia Pacific, Europe, North America, Rest of the World (RoW).

The global liquid biopsy market is highly competitive. Top players covered in Global Liquid Biopsy Market Study are Adaptive Biotechnologies Corp., Agilent Technologies Inc., Amoy Diagnostics Co. लिमिटेड, Becton Dickinson and Company, Berry Genomics Co. लिमिटेड, BGI Group, Biocartis Group, Biocept Inc., Biodesix Inc., Biolidics Limited, Bio-Rad Laboratories Inc., Bio-Techne Corp., CareDx Inc., Danaher Corp., Eurofins Scientific, EXACT Sciences Corporation, Illumina Inc., Koninklijke Philips N.V., Merck KGaA, Myriad Genetics Inc., NeoGenomics Laboratories Inc., OncoCyte Corporation, Oxford Nanopore Technologies Limited, Pacific Biosciences of California Inc., Qiagen N.V., Roche Holding AG, Takara Bio Inc., Thermo Fisher Scientific Inc., VolitionRx Limited.

यह रिपोर्ट इस उद्योग में सक्रिय कंपनियों और संगठनों के लिए एक अमूल्य संसाधन है. It provides a cohesive picture of the liquid biopsy market to help drive informed decision making for industry executives, नीति निर्माताओं, अकादमिक, और विश्लेषक.

रिपोर्ट का दायरा

Therapy: oncology, noninvasive prenatal testing (NIPT), others (e.g. organ transplant)
Application: diagnosis, early detection/screening, monitoring, therapy guidance
Biomarker type: cell-free nucleic acids, circulating tumor cells, others
Technology: next-generation sequencing (NGS), polymerase chain reaction (PCR), others
Region: एशिया प्रशांत, Europe, North America, Rest of the World (RoW)
Years considered: यह रिपोर्ट उस अवधि को कवर करती है 2018 को 2028

हितधारकों के लिए मुख्य लाभ

– Get a comprehensive picture of the global liquid biopsy market
– विकास क्षेत्रों और निवेश के रुझानों को इंगित करें

विषयसूची

Part 1. Introduction
– Scope of the study
– Study period
– Geographical scope
– Research methodology
Part 2. Liquid biopsy market overview
Part 3. Market breakdown by therapy
– Oncology
– Noninvasive prenatal testing (NIPT)
– अन्य (e.g. organ transplant)
Part 4. Market breakdown by application
– Diagnosis
– Early detection/screening
– Monitoring
– Therapy guidance
Part 5. Market breakdown by biomarker type
– Cell-free nucleic acids
– Circulating tumor cells
– अन्य
Part 6. Market breakdown by technology
– Next-generation sequencing (NGS)
– Polymerase chain reaction (PCR)
– अन्य
Part 7. Market breakdown by region
– एशिया प्रशांत
– Europe
– North America
– Rest of the World (RoW)
Part 8. Key companies
– Adaptive Biotechnologies Corp.
– Agilent Technologies Inc.
– Amoy Diagnostics Co., लिमिटेड.
– Becton, Dickinson and Company
– Berry Genomics Co., लिमिटेड.
– BGI Group
– Biocartis Group
– Biocept, इंक.
– Biodesix, इंक.
– Biolidics Limited
– Bio-Rad Laboratories, इंक.
– Bio-Techne Corp.
– CareDx, इंक.
– Danaher Corp.
– Eurofins Scientific
– EXACT Sciences Corporation
– Illumina, इंक.
– Koninklijke Philips N.V.
– Merck KGaA
– Myriad Genetics, इंक.
– NeoGenomics Laboratories, इंक.
– OncoCyte Corporation
– Oxford Nanopore Technologies Limited
– Pacific Biosciences of California, इंक.
– Qiagen N.V.
– Roche Holding AG
– Takara Bio Inc.
– Thermo Fisher Scientific Inc.
– VolitionRx Limited
स्ट्रेटेजीहेलिक्स के बारे में
अस्वीकरण